Practical protocol for tirzepatide levocarnitine For researchers who decide to proceed with the tirzepatide levocarnitine compound, here is a structured approach based on available evidence and best practices
As you said, it has the component of anti inflammatory support, it's being studied for autoimmune disease
Again, while there was a ~60% increase SOD in the present study after 90 days of supplementation, the placebo group had the same increase (Fig 2)
Importantly, while the incidence of adverse effects was similar between ALC and placebo/no intervention, ALC was associated with a lower incidence of adverse effects compared to antidepressant medications
Amongst these, we recommend initial therapy with antihistamines and SSRIs, followed by IFN- therapy for more severe and refractory cases, and reserve treatment with JAK2 inhibitors for high-risk patients with IFN--resistant pruritus
Baker, A